About VGX Pharmaceuticals
VGX Pharmaceuticals is a Healthcare company based in Blue Bell (United States) founded in 2002, and was acquired by Inovio Pharmaceuticals in July 2008. DNA-based vaccines for infectious diseases and cancers are developed. VGX Pharmaceuticals has raised $4.5 million across 4 funding rounds from investors including NIH, Korean Development Bank and Inovio Pharmaceuticals. Its focus areas include Diversified Pharmaceuticals, Life Sciences, Immunotherapy and Vaccine. Its competitors include Novavax, Dyne Therapeutics and Immunomic Therapeutics; 1 of its 3 listed competitors has raised funding.
Company details
VGX Pharmaceuticals was established in 2002 in Blue Bell, United States, within the biotechnology sector. Focus was placed on DNA-based vaccines targeting infectious diseases and cancers, alongside related devices. Key clinical programs encompassed Pennvax-B for HIV prevention, VGX-1027 for inflammatory conditions, VGX-3100 for cervical cancer treatment, and the Cellectra electroporator for DNA delivery. Operations concluded with a merger into Inovio Pharmaceuticals in July 2008.
- Headquarters Blue Bell, United States
- Stage Acquired
- SectorsHealthcare
- Website vgxp.com
- Social LinkedIn
- Acquired by Inovio Pharmaceuticals (Jul 2008)
- Total Equity Funding$4.5M (USD)
in 4 rounds
- Latest Funding Round$23.5M (USD), Grant
Oct 2008
- InvestorsNIH
& 3 more
- Acquired byInovio Pharmaceuticals
(Jul 2008)
Funding Insights of VGX Pharmaceuticals
VGX Pharmaceuticals has successfully raised a total of $4.5M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $23.5 million completed in October 2008. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.5M
- Total Rounds 4
- Last Round Grant — $23.5M
- First Round $425,000
(May 2003)
- Investors Count 3
All 4 funding rounds of VGX Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2008 | $23.5M | Grant | – | – | |
| Sep 2007 | $4M | Series A | – | – | |
| Feb 2004 | $499,840 | Seed | – | – | |
| May 2003 | $425,000 | Grant | – | – |
4 investors in total: 4 institutional.
Investors in VGX Pharmaceuticals
VGX Pharmaceuticals has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Korean Development Bank and Inovio Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| bioadvance.com | ||||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Development financing and commercial banking are provided in South Korea. | 1954 | kdb.co.kr | Seoul, South Korea | |
Developer of vaccines for the treatment of cancer and infectious diseases | 1983 | inovio.com | Plymouth Meeting, United States |
Investor details for VGX Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of VGX Pharmaceuticals
4 dated milestones of VGX Pharmaceuticals across 6 years, from founding to its latest funding, stage changes and deals.
- Founded VGX Pharmaceuticals is founded.
- Funding First funding round of $425K.
- Exit Acquired by Inovio Pharmaceuticals.
- Funding Latest funding round, Grant, of $23.5M.
Competitors of VGX Pharmaceuticals
VGX Pharmaceuticals has 3 listed competitors in our database, 1 of them funded. They include Novavax, Dyne Therapeutics and Immunomic Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| novavax.com | 1987 | Gaithersburg, United States | 184 | Novel vaccines are developed using nanoparticle and matrix adjuvant technology. | ||
| dyne-tx.com | 2017 | Cambridge, United States | 116 | Nucleic acid therapies for rare diseases are developed. | ||
| immunomix.com | 2005 | Rockville, United States | $104.44M | 51 | Immunomic Therapeutics is engaged in developing nucleic acid immunotherapy platforms. |
Detailed competitors of VGX Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Immunology & Cancer Therapeutics
3 companies that operate in the same segment as VGX Pharmaceuticals (Immunology & Cancer Therapeutics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | |||
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about VGX Pharmaceuticals
VGX Pharmaceuticals was founded in 2002 and raised its 1st funding round 1 year after it was founded.
VGX Pharmaceuticals is headquartered in Blue Bell, United States. It is registered at Blue Bell, Pennsylvania, United States.
VGX Pharmaceuticals is a funded company, having raised a total of $4.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $425K, raised on May 2003.
VGX Pharmaceuticals was established in 2002 in Blue Bell, United States, within the biotechnology sector. Focus was placed on DNA-based vaccines targeting infectious diseases and cancers, alongside related devices. Key clinical programs encompassed Pennvax-B for HIV prevention, VGX-1027 for inflammatory conditions, VGX-3100 for cervical cancer treatment, and the Cellectra electroporator for DNA delivery. Operations concluded with a merger into Inovio Pharmaceuticals in July 2008.
VGX Pharmaceuticals's top competitors include Dyne Therapeutics, Novavax and Immunomic Therapeutics.
VGX Pharmaceuticals has 4 investors. Key investors include NIH, Korean Development Bank, Inovio Pharmaceuticals, and BioAdvance.
Yes. VGX Pharmaceuticals was acquired by Inovio Pharmaceuticals in July 2008.